ECE2018 Poster Presentations: Thyroid Thyroid cancer (88 abstracts)
Division of Endocrinology and Department of Nuclear Medicine, Theagenio Cancer Hospital, Thessaloniki, Greece.
Introduction: Evidence supports the prognostic value of preablative stimulated thyroglobulin (ps-Tg) for recurrent and persistent disease in patients with differentiated thyroid cancer (DTC). The correlation of ps-Tg with therapeutic response however has been less studied.
Objective: To study the correlation of ps-Tg and the trend of serial preablative thyroglobulin measurements(DTg) with the response to treatment restaging system proposed in 2015 American Thyroid Association guidelines.
Methods: We conducted a retrospective study on patients with DTC who underwent total thyroidectomy and radioactive iodine (RAI) ablation in a tertiary referral hospital in 2009 and 2010. Patients with missing data or positive anti-Tg Abs were excluded from the study and the rest were divided in three groups in terms of ps-Tg levels: group 1, ps-Tg<1 ng/ml (n=48), group 2, 1≥ps-Tg≤10 ng/ml (n=48), group 3, ps-Tg >10 ng/ml (n=19). Responses to therapy were divided in excellent (ER), biochemical incomplete (BIR), indeterminate (IR) and structural incomplete response (SIR) according to the new response to treatment system.
Results: 115 patients were followed for a median of 60 months. SIR was detected in 3.4% in group 1, 8% in group 2, 20% in group 3. However, results were not statistically significant in the studied series (χ2=3.435, P=0.179).
Conclusion: Preablative thyroglobulin may be correlated to therapeutic response.